Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-Effectiveness Analysis of Herpes Zoster Vaccination in a Chinese Population: Recombinant Subunit Vaccine versus Live Attenuated Vaccine

1 Aug 2024

Abstract excerpt

BACKGROUND: Currently, the recombinant subunit vaccine and live attenuated vaccine in the prevention of herpes zoster are approved for marketing in China. This study aims to evaluate the cost-effectiveness of the recombinant subunit vaccine and the live attenuated vaccine in the Chinese population. METHODS: A decision tree-Markov analysis model was utilized to estimate expected costs and quality-adjusted life...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Herpesvirus Infections and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39203998
DOI: 10.3390/vaccines12080872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Cost-Effectiveness Analysis of Herpes Zoster Vaccination in a Chinese Population: Recombinant Subunit Vaccine versus Live Attenuated VaccinePMID 39203998Read ↗

Epidemiology and clinical profile of herpes zoster in the varicella vaccine era: A case series studySemantic proximity Read ↗

The recombinant shingles vaccine is associated with lower risk of dementiaSemantic proximity Read ↗

Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocolSemantic proximity Read ↗

Efficacy and side effects of the Herpes Zoster vaccine in immunocompromised individuals – a systematic reviewSemantic proximity Read ↗

Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune‐Mediated Inflammatory Diseases in the USSemantic proximity Read ↗

Evaluating Cost-effectiveness of 9-valent HPV Vaccination for Men Who Have Sex with Men by HIV Status in Hong KongSemantic proximity Read ↗

Recombinant zoster vaccine and the risk of dementiaSemantic proximity Read ↗

Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.